Cervical ripening with intravaginal prostaglandin E2 gel.
Fifty-four patients were randomized in a double blind fashion into either a placebo group or a group treated with a 3 mg dose of an intravaginal prostaglandin E2 gel. The group receiving the prostaglandin E2 gel had a mean change in cervical score of 2.7 while the patients in the placebo group had no significant change. Even though a significantly higher number of patients in the prostaglandin group went into spontaneous labor, the incidence of cesarean section was not different between the two groups. Upon comparing the conflicting reports of various studies on the subject, it is concluded that the method of product preparation, particularly the source of prostaglandin E2 utilized and the choice of drug vehicle, may be important variables in determining treatment success, as measured in terms of decreased cesarean section rate.
Curet
L B
LB
University of Wisconsin Perinatal Cancer at Meriter/Madison General Hospital.
Gauger
L J
LJ
D000282:Administration, Intravaginal; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D002585:Cesarean Section; D015232:Dinoprostone / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007751:Labor, Induced; D010570:Pessaries; D011247:Pregnancy; D011446:Prospective Studies; D011897:Random Allocation
D015232:Dinoprostone